ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,002,967 | -9.3% | 48,127 | +4.2% | 0.00% | 0.0% |
| Q2 2023 | $1,106,274 | +45.5% | 46,191 | +14.4% | 0.00% | 0.0% |
| Q1 2023 | $760,065 | +5.1% | 40,386 | -11.1% | 0.00% | 0.0% |
| Q4 2022 | $723,309 | +10.8% | 45,434 | +13.9% | 0.00% | 0.0% |
| Q3 2022 | $653,000 | -2.0% | 39,903 | -15.6% | 0.00% | 0.0% |
| Q2 2022 | $666,000 | -29.4% | 47,264 | +21.3% | 0.00% | 0.0% |
| Q1 2022 | $944,000 | +46.1% | 38,968 | +40.7% | 0.00% | +100.0% |
| Q4 2021 | $646,000 | +189.7% | 27,693 | +219.7% | 0.00% | – |
| Q1 2021 | $223,000 | -63.6% | 8,661 | -24.5% | 0.00% | -100.0% |
| Q4 2020 | $613,000 | -30.0% | 11,471 | -46.0% | 0.00% | 0.0% |
| Q3 2020 | $876,000 | -81.9% | 21,230 | -78.8% | 0.00% | -87.5% |
| Q2 2020 | $4,845,000 | +2.5% | 99,958 | -10.6% | 0.01% | 0.0% |
| Q1 2020 | $4,726,000 | -17.8% | 111,864 | -16.8% | 0.01% | +14.3% |
| Q4 2019 | $5,750,000 | +4.9% | 134,397 | -11.8% | 0.01% | +16.7% |
| Q3 2019 | $5,484,000 | +55.8% | 152,381 | +15.7% | 0.01% | +50.0% |
| Q2 2019 | $3,520,000 | +26.3% | 131,682 | +26.9% | 0.00% | +33.3% |
| Q1 2019 | $2,786,000 | +130.6% | 103,777 | +38.9% | 0.00% | +200.0% |
| Q4 2018 | $1,208,000 | +82.2% | 74,727 | +153.1% | 0.00% | 0.0% |
| Q1 2018 | $663,000 | -39.8% | 29,525 | -19.2% | 0.00% | 0.0% |
| Q4 2017 | $1,101,000 | -24.4% | 36,563 | -5.4% | 0.00% | -50.0% |
| Q3 2017 | $1,456,000 | +35.1% | 38,660 | 0.0% | 0.00% | +100.0% |
| Q2 2017 | $1,078,000 | -11.1% | 38,660 | +9.7% | 0.00% | -50.0% |
| Q1 2017 | $1,212,000 | +141.9% | 35,246 | +128.4% | 0.00% | +100.0% |
| Q2 2016 | $501,000 | -44.3% | 15,434 | -52.0% | 0.00% | -50.0% |
| Q1 2016 | $900,000 | -33.1% | 32,185 | -14.7% | 0.00% | 0.0% |
| Q4 2015 | $1,346,000 | +169.2% | 37,751 | +149.5% | 0.00% | +100.0% |
| Q3 2015 | $500,000 | -69.1% | 15,133 | -60.8% | 0.00% | -66.7% |
| Q2 2015 | $1,618,000 | +78.8% | 38,619 | +39.0% | 0.00% | +50.0% |
| Q1 2015 | $905,000 | -15.6% | 27,774 | -17.8% | 0.00% | 0.0% |
| Q4 2014 | $1,072,000 | +15.9% | 33,774 | -9.6% | 0.00% | -33.3% |
| Q3 2014 | $925,000 | -58.8% | 37,374 | -62.4% | 0.00% | -50.0% |
| Q2 2014 | $2,245,000 | +247.0% | 99,374 | +274.0% | 0.01% | +200.0% |
| Q1 2014 | $647,000 | -66.4% | 26,574 | -65.5% | 0.00% | -66.7% |
| Q4 2013 | $1,926,000 | -20.7% | 77,074 | -12.8% | 0.01% | -33.3% |
| Q3 2013 | $2,428,000 | +67.9% | 88,374 | +10.9% | 0.01% | +80.0% |
| Q2 2013 | $1,446,000 | +203.1% | 79,674 | -22.2% | 0.01% | +150.0% |
| Q4 2012 | $477,000 | – | 102,474 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |